2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1088

Effect of Training on Knee Torsional Stiffness and Its Relationship to Tibial Compressive and Anterior Shear Forces in Recreational Female Runners
Abstract Number: 316

Effect of Vitamin D on Effusion-Synovitis in Knee Osteoarthritis: a Randomized Controlled Trial
Abstract Number: 2859

Effect of Weight on Efficacy of Certolizumab Pegol in Patients with Axial Spondyloarthritis
Abstract Number: 2006

Effect Size of the Anti-Aggrecanase-2 Monoclonal Antibody CRB0017 in Rodent Models of Osteoarthritis
Abstract Number: 1180

Effective Knowledge Transfer: A Demonstration of Video Illustration in the Immunology Curriculum for Rheumatology Trainees
Abstract Number: 2871

Effectiveness and Safety of Golimumab in the Treatment of Ankylosing Spondylitis over a 12 Month Period
Abstract Number: 2866

Effectiveness and Safety of Golimumab in the Treatment of Psoriatic Arthritis over a 12 Month Period
Abstract Number: 2753

Effectiveness and Safety of Tocilizumab in Biologics-Naive RA Patients – Postmarketing Surveillance for Investigating Success in Achieving Clinical and Functional Remission and Sustaining Efficacy with Tocilizumab in Biologics-Naive RA Patients (FIRST Bio) Study
Abstract Number: 953

Effectiveness of a Progressive Resistence Strength Programme on Hand Osteoarthritis: A Randomized Crontrolled Trial
Abstract Number: 2240

Effectiveness of Allopurinol in Achieving and Sustaining Target Serum Urate: A Study Using Large Intergrated National Health Network
Abstract Number: 320

Effectiveness of Bracing in Elderly with Knee Osteoartritis: A Randomized Controlled Trial
Abstract Number: 2288

Effectiveness of Dry Needling and Exercise in Dizziness Caused By Cervical Myofascial Pain Syndrome
Abstract Number: 1655

Effectiveness of Monotherapy in Rheumatoid Arthritis (RA) Patients Initiating a Tumor Necrosis Factor Inhibitor (TNFi) Vs a Non-TNFi in a Large US Commercial and Medicare Advantage Plan
Abstract Number: 1091

Effectiveness of Multidisciplinary Pain Rehabilitation Programs for Patients with Fibromyalgia Syndrome: A Systematic Review
Abstract Number: 2079

Effectiveness of Renoprotective Approaches in Lupus Nephritis: More Than Just Immunosuppression

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].